CLINUVEL 360
Strategic Updates
FAQs
CLINUVEL’s mission is supported by a clear vision, with principal values and strategic plans to support the advance of the business towards a diversified and sustainable pharmaceutical group. Since the commencement of commercial distribution of SCENESSE® (afamelanotide 16mg), in Europe from June 2016 and in the USA from April 2020, CLINUVEL has generated annual revenues growth to record seven years of consecutive annual profit. The balance sheet is strong with no bank debt and sufficient accumulated cash reserves to finance its expansion. From this position of strength, CLINUVEL is expanding the product range and clinical program to develop treatments for a range of conditions of the skin and brain with unmet needs.
Like any business, CLINUVEL faces a range of risks to the achievement of its objectives, but it has a track record of successfully innovating a first-in-class treatment therapy for adult patients who experience an acute phototoxic reaction to light. CLINUVEL is translating its technology to the non-pharmaceutical sector through a range of PhotoCosmetic products to provide healthcare solutions to targeted audiences of the general population.
CLINUVEL has an experienced Board of Directors and management team with dedicated and committed staff to effectively implement its plans in the ensuing years.
CLINUVEL’s primary listing is on the Australian Securities Exchange (ASX), with ordinary shares traded under the code, CUV.
The stock is also traded on:
- the Börse Frankfurt, Germany, under the code, UR9; and
- the over-the-counter securities market in the USA, as a sponsored Level 1, American Depositary Receipt (ADR), under the code, CLVLY.
CLVLY is issued at a ratio of 1 ADR: 1 Ordinary Share of CUV. The Bank of New York Mellon is the depositary bank for CLVLY.
CLINUVEL does not issue stock directly to investors. Please contact a financial advisor for more information on investing.
CLINUVEL’s American Depositary Receipt (ADR) listing (CLVLY) is sponsored by the Bank of New York Mellon. BNY-Mellon provides comprehensive information on their website covering ADRs and how they work for investors, which may be of interest. The stock CLVLF is not a company-sponsored Depositary Receipt (DR), rather it is a broker sponsored DR. Therefore, it is the individual broker’s responsibility to ensure the DR is backed by a purchase of the ASX listed CUV share in Australia. We encourage you to contact your broker for more information on investing.
CLINUVEL maintains its Australian Securities Exchange (ASX) shareholder registry with Computershare. ASX Shareholders can access the Company’s share registry with Computershare online and view their Security Holdings (Account Details, Balances, Communication Details) and Shareholding Records. For all enquiries related to your ASX shareholding with CLINUVEL, contact:
Computershare
The Registrar
Computershare Investor Services Pty Limited
GPO Box 2975
Australia
(Aus) 1300 555 159
(International) +61 (0)3 9415 4062
You can access the Computershare website here
Within the USA, CLINUVEL shares can be purchased through the Bank of NY Mellon’s Level 1 American Depositary Receipt (ADR) program under the ticker code CLVLY. For more information on ADRs, log onto the Bank of NY Mellon’s ADR investors website here.
If an ADR holder wishes to vote on resolutions of meetings of the Company, it is recommended they either cancel their ADRs and acquire CUV or transfer their ADRs to CUV and hold the underlying security as an ordinary share. ADR holders should seek advice on this action from their broker and/or financial advisor.
Alternatively, an ADR holder would need to discuss their intention to vote with their broker which would need to be facilitated on a best endeavours basis through the Bank of New York Mellon, noting this may be on a fee for service basis.
As a Level 1 sponsored ADR program, and consistent with market practice of other ASX-listed companies with similar Level 1 sponsored ADR programs, the Company does not disseminate proxy notices to ADR holders. The Company remains at arms-length to the capacity of Bank of New York Mellon to process individual proxy forms from ADR holders.
CLINUVEL’s financial year end is 30 June.
CLINUVEL’s independent auditor is Grant Thornton Audit Pty Ltd.
Annual Reports can be found on the CLINUVEL website here. Holders of the ASX listed stock may choose to receive a printed copy of the Annual Report by changing their preferences with Computershare.
All releases of information to the Australian Securities Exchange covering company news and financial results can be found on the CLINUVEL website. CLINUVEL also sends regular Email Updates on its progress, as well as published announcements and analyst reports.
Historical data for CLINUVEL shares can be found on the Share Price page of CLINUVEL’s website here.
The results can be found on the Announcements page of CLINUVEL’s website here.
CLINUVEL announces annual and half year reports, due by the end of August and February, respectively of each year.
The Financial Summary available on this website provides the results achieved for the past five years. Details are contained in Annual Reports, also available on this website.
CLINUVEL has paid a dividend on the earnings achieved in each of the past six financial years to 30 June 2023. The details may be found in the Financial Summary on this website.